Health
Experts laud injection that reportedly offers 100% protection against HIV/AIDS
- Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to a new study.
- There were no infections among the young women and girls who received the shots in a study of about 5,000 participants in South Africa and Uganda.
- The shots, made by U.S. drugmaker Gilead and sold as Sunlenca, are currently approved as a treatment for HIV in several regions.
Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday.
There were no infections in the young women and girls that got the shots in a study of about 5,000 in South Africa and Uganda, researchers reported. In a group given daily prevention pills, roughly 2% ended up catching HIV from infected sex partners.
“To see this level of protection is stunning,” said Salim Abdool Karim of the injections. He is director of an AIDS research center in Durban, South Africa, who was not part of the research.
PIONEER OF AMERICA’S GLOBAL HIV/AIDS PROGRAM RECALLS HOPE AFTER YEARS OF DESPAIR
The shots made by U.S. drugmaker Gilead and sold as Sunlenca are approved in the U.S., Canada, Europe and elsewhere, but only as a treatment for HIV. The company said it is waiting for results of testing in men before seeking permission to use it to protect against infection.
A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation’s Masiphumelele Research Site in Cape Town, South Africa, on July 23, 2024. The twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published on Wednesday. (AP Photo/Nardus Engelbrecht)
The results in women were published Wednesday in the New England Journal of Medicine and discussed at an AIDS conference in Munich. Gilead paid for the study and some of the researchers are company employees. Because of the surprisingly encouraging results, the study was stopped early and all participants were offered the shots, also known as lenacapavir.
While there are other ways to prevent HIV infection, like condoms or daily pills, consistent use has been a problem in Africa. In the new study, only about 30% of participants given Gilead’s Truvada or Descovy prevention pills actually took them — and that figure dropped over time.
The prospect of a twice-a-year shot is “quite revolutionary news” for our patients, said Thandeka Nkosi, who helped run the Gilead research at the Desmond Tutu Health Foundation in Masiphumelele, South Africa. “It gives participants a choice and it just eliminates the whole stigma around taking pills” to prevent HIV.
HIV/AIDS CAN BE ELIMINATED BY 2030 IF COUNTRIES TAKE THE CORRECT STEPS, ACCORDING TO UN
Experts working to stop the spread of AIDS are excited about the Sunlenca shots but are concerned Gilead hasn’t yet agreed on an affordable price for those who need them the most. The company said it would pursue a “voluntary licensing program,” suggesting that only a select number of generic producers would be allowed to make them.
“Gilead has a tool that could change the trajectory of the HIV epidemic,” said Winnie Byanyima, executive director of the Geneva-based U.N. AIDS agency.
A pharmacist holds a vial of lenacapavir at the Desmond Tutu Health Foundation’s Masiphumelele Research Site in Cape Town, South Africa, on July 23, 2024. (AP Photo/Nardus Engelbrecht)
She said her organization urged Gilead to share Sunlenca’s patent with a U.N.-backed program that negotiates broad contracts allowing generic drugmakers to make cheap versions of drugs for poorer countries worldwide. As an HIV treatment, the drug costs more than $40,000 a year in the U.S., although what individuals pay varies.
Dr. Helen Bygrave of Doctors Without Borders said in a statement that the injections could “reverse the epidemic if it is made available in the countries with the highest rate of new infections.” She urged Gilead to publish a price for Sunlenca that would be affordable for all countries.
In a statement last month, Gilead said it was too early to say how much Sunlenca would cost for prevention in poorer countries. Dr. Jared Baeten, Gilead’s senior vice president of clinical development, said the company was already talking to generics manufacturers and understood how “deeply important it is that we move at speed.”
Another HIV prevention shot, Apretude, which is given every two months, is approved in some countries, including in Africa. It sells for about $180 per patient per year, which is still too pricey for most developing countries.
A lab technician works with vials of lenacapavir at the Desmond Tutu Health Foundation’s Masiphumelele Research Site in Cape Town, South Africa, on July 23, 2024. (AP Photo/Nardus Engelbrecht)
Byanyima said the people who need long-lasting protection the most include women and girls who are victims of domestic violence and gay men in countries where same-sex relationships are criminalized. According to UNAIDS, 46% of new HIV infections globally in 2022 were in women and girls, who were three times more likely to get HIV than males in Africa.
Byanyima compared the news about Sunlenca to the discovery decades ago of AIDS drugs that could turn HIV infection from a death sentence into a chronic illness. Back then, South African President Nelson Mandela suspended patents to allow wider access to the drugs; the price later dropped from about $10,000 per patient per year to about $50.
Olwethu Kemele, a health worker at the Desmond Tutu Health Foundation, predicted the shots could boost the number of people coming in for HIV prevention and slow the virus’ spread. She said young women often hide the pills to avoid questions from boyfriends and family members. “It makes it hard for the girls to continue,” she said.
In a report on the state of the global epidemic released this week, UNAIDS said that fewer people were infected with HIV in 2023 than at any point since the late 1980s. Globally, HIV infects about 1.3 million people every year and kills more than 600,000, mainly in Africa. While significant progress has been made in Africa, HIV infections are rising in Eastern Europe, Latin America and the Middle East.
In other research presented at the AIDS conference, Andrew Hill of the University of Liverpool and colleagues estimated that once production of Sunlenca is expanded to treat 10 million people, the price should fall to about $40 per treatment. He said it was critical that health authorities get access to Sunlenca as soon as possible.
“This is about as close as you can get to an HIV vaccine,” he said.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A deadly, drug-resistant fungus already spreading rapidly through U.S. hospitals is becoming even more threatening worldwide, though there may be hope for new treatments, according to a new scientific review.
Candida auris (C. auris), often described as a “superbug fungus,” is spreading globally and increasingly resisting human immune systems, Hackensack Meridian Center for Discovery and Innovation (CDI) researchers said in a review published in early December.
The findings reinforce prior CDC warnings that have labeled C. auris an “urgent antimicrobial threat” — the first fungal pathogen to receive that designation — as U.S. cases have surged, particularly in hospitals and long-term care centers.
DANGEROUS SPIKE IN SUPERBUG INFECTIONS SURGES ACROSS US AS EXPERTS SHARE CAUTIONS
Approximately 7,000 cases were identified across dozens of U.S. states in 2025, according to the CDC, and it has reportedly been identified in at least 60 countries.
Candida auris is a drug-resistant fungus spreading in hospitals worldwide. (Nicolas Armer/Picture Alliance via Getty Images)
The review, published in Microbiology and Molecular Biology Reviews, helps explain why the pathogen is so difficult to contain and warns that outdated diagnostics and limited treatments lag behind. It was conducted by Dr. Neeraj Chauhan of the Hackensack Meridian CDI in New Jersey, Dr. Anuradha Chowdhary of the University of Delhi’s Medical Mycology Unit and Dr. Michail Lionakis, chief of the clinical mycology program at the National Institutes of Health.
Their findings stress the need to develop “novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests and to develop immune- and vaccine-based adjunct modalities for the treatment of high-risk patients,” the researchers said in a statement.
GROWING ANTIBIOTIC CRISIS COULD TURN BACTERIAL INFECTIONS DEADLY, EXPERTS WARN
“In addition, future efforts should focus on raising awareness about fungal disease through developing better surveillance mechanisms, especially in resource-poor countries,” they added. “All these developments should help improve the outcomes and prognosis of patients afflicted by opportunistic fungal infections.”
Candida auris can survive on skin and hospital surfaces, allowing it to spread easily. (iStock)
First identified in 2009 from a patient’s ear sample in Japan, C. auris has since spread to dozens of countries, including the U.S., where outbreaks have forced some hospital intensive care units to shut down, according to the researchers.
The fungus poses the greatest risk to people who are already critically ill, particularly those on ventilators or with weakened immune systems. Once infected, about half of patients may die, according to some estimates.
FLU BY STATE: WHERE THIS SEASON’S HIGHLY CONTAGIOUS VARIANT IS SPREADING THE MOST
Unlike many other fungi, C. auris can survive on human skin and cling to hospital surfaces and medical equipment, allowing it to spread easily in healthcare settings.
“It is resistant to multiple antifungal drugs, and it tends to spread in hospital settings, including on equipment being used on immunocompromised and semi-immunocompromised patients, such as ventilators and catheters,” Dr. Marc Siegel, Fox News senior medical analyst and clinical professor of medicine at NYU Langone, previously told Fox News Digital.
Scientists say the unique cell wall structure of C. auris makes it harder to kill. (iStock)
It is also frequently misdiagnosed, delaying treatment and infection control measures.
“Unfortunately, symptoms such as fever, chills and aches may be ubiquitous, and it can be mistaken for other infections,” Siegel said.
In September, he said intense research was ongoing to develop new treatments.
Only four major classes of antifungal drugs are currently available, and C. auris has already shown resistance to many of them. While three new antifungal drugs have been approved or are in late-stage trials, researchers warn that drug development has struggled to keep pace with the fungus’s evolution.
CLICK HERE FOR MORE LIFESTYLE STORIES
Despite the sobering findings, there is still room for cautious optimism.
The fungus can cling to skin and hospital surfaces, aiding its spread. (iStock)
In separate research published in December, scientists at the University of Exeter in England discovered a potential weakness in C. auris while studying the fungus in a living-host model.
The team found that, during infection, the fungus activates specific genes to scavenge iron, a nutrient it needs to survive, according to their paper, published in the Nature portfolio journal Communications Biology in December.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Because iron is essential for the pathogen, researchers believe drugs that block this process could eventually stop infections or even allow existing medications to be repurposed.
“We think our research may have revealed an Achilles’ heel in this lethal pathogen during active infection,” Dr. Hugh Gifford, a clinical lecturer at the University of Exeter and co-author of the study, said in a statement.
New research is underway to develop better treatments and diagnostics for C. auris. (iStock)
As researchers race to better understand the fungus, officials warn that strict infection control, rapid detection and continued investment in new treatments remain critical.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Health experts emphasize that C. auris is not a threat to healthy people.
Fox News Digital has reached out to the CDI researchers and additional experts for comment.
Fox News Digital’s Angelica Stabile contributed reporting.
New flu strain emerging as a severe health threat
Fox News senior medical analyst Dr. Marc Siegel joins ‘America’s Newsroom’ to warn of a new strain of the flu that is spiking hospitalizations across the country and newfound risks of medical marijuana’s link to psychosis.
NEWYou can now listen to Fox News articles!
The New York State Department of Health reported a record surge in influenza activity, with 71,123 positive flu cases recorded statewide during the week ending December 20.
Health officials said the figure represents the highest number of flu cases ever reported in a single week since influenza became a reportable disease in New York in 2004.
State health data show the weekly total reflects a 38% increase from the previous reporting period, signaling a rapidly intensifying flu season.
There have been 189,312 reported positive flu cases so far this season, while influenza-related hospitalizations rose 63% in the most recent week.
FLU BY STATE: WHERE THIS SEASON’S HIGHLY CONTAGIOUS VARIANT IS SPREADING THE MOST
New York reported the highest weekly total of cases ever recorded since influenza became reportable in 2004. (iStock)
“We are seeing the highest number of flu cases ever recorded in a single week in New York state,” Health Commissioner Dr. James McDonald said in a press release.
There have been 189,312 reported flu cases so far this season, with influenza-related hospitalizations increasing 63% in the most recent week. (iStock)
Earlier this month, the department declared influenza prevalent statewide, a designation that requires unvaccinated health care workers to wear masks in patient care settings.
SURGE IN WHOOPING COUGH CASES IN SOUTHERN STATE PROMPTS HEALTH ALERTS
Health officials continue to emphasize that vaccination remains the most effective way to prevent severe illness and hospitalization from influenza.
CLICK HERE FOR MORE HEALTH STORIES
New Yorkers who have not yet received a seasonal flu shot are still encouraged to do so, with experts saying vaccination can offer protection even later in the season.
Health officials continue to urge New Yorkers to take preventive steps, including vaccination and staying home when sick, to limit further spread. (iStock)
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
To help limit further spread, the department advises individuals experiencing flu-like symptoms — including fever, cough, sore throat, or body aches — to stay home. State health officials also recommend frequent handwashing, using hand sanitizer, and avoiding close contact with sick individuals.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
For those who become ill, officials say antiviral medications are available and are most effective when started within 48 hours of symptom onset.
Health officials also added that people at higher risk for complications should contact a health care provider promptly for evaluation and possible treatment.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The department noted that flu activity typically peaks in January, meaning case counts could continue to climb in the weeks ahead.
What we know about the alleged ISIS-inspired New Year’s Eve terror suspect
Hochul orders NY landmarks, including One World Trade Center, lit green for Muslim American Heritage Month
Detroit Lions vs. Chicago Bears: How to watch today’s NFL game, kickoff time, TV channel and more
What is next for San Francisco 49ers and who to root for Week 18
Can North Texas solve our housing price crisis?
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Crans Montana organises solemn march for the victims • FRANCE 24 English
Kamala Harris blasts Trump administration’s capture of Venezuela’s Maduro as ‘unlawful and unwise’
US Republicans back Trump on Venezuela amid faint MAGA dissent
Who is Delcy Rodríguez, Venezuela’s leader after Maduro’s capture? | CNN
Trump says US will ‘run Venezuela’ after seizing President Maduro in military assault | BBC News
-
Entertainment1 week agoHow the Grinch went from a Yuletide bit player to a Christmas A-lister
-
Connecticut1 week agoSnow Accumulation Estimates Increase For CT: Here Are The County-By-County Projections
-
World6 days agoHamas builds new terror regime in Gaza, recruiting teens amid problematic election
-
Indianapolis, IN1 week agoIndianapolis Colts playoffs: Updated elimination scenario, AFC standings, playoff picture for Week 17
-
Southeast1 week agoTwo attorneys vanish during Florida fishing trip as ‘heartbroken’ wife pleads for help finding them
-
Business1 week agoGoogle is at last letting users swap out embarrassing Gmail addresses without losing their data
-
World1 week agoSnoop Dogg, Lainey Wilson, Huntr/x and Andrea Bocelli Deliver Christmas-Themed Halftime Show for Netflix’s NFL Lions-Vikings Telecast
-
World1 week agoBest of 2025: Top five defining moments in the European Parliament